KRBP News

Updated Monday, 11/9. The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead. Oncology biotech IN8bio (INAB) plans to raise $75 million at a $325 million market cap. IN8bio is focused on developing cancer therapies by employing allogeneic, autologous...read more

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. The largest deal of the week, Array Technologies (ARRY) upsized and priced above the range to raise $1.0...read more

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, raised $15 million by offering 1.3 million shares at $12, the low end of the range of $12 to $14. Kiromic BioPharma plans to list on the Nasdaq under the symbol KRBP. ThinkEquity acted as sole bookrunner on the deal. ...read more

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, lowered the proposed deal size for its upcoming IPO on Tuesday. In its latest filing, the company also added Paulson Investment as an underwriter. The Houston, TX-based company now plans to raise $15 million by offering 1.2 million shares at a price range of $12 to $14. The...read more